IP Library Granted Patent US 10,525,226
Granted Patent B2
US 10,525,226 · App. 14/712,419 · Granted Jan 7, 2020

Systems and methods for indicating lifetime of an NO2-to-NO reactor cartridge used to deliver NO for inhalation therapy to a patient

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,525,226
App. No.
14/712,419
Granted
Jan 7, 2020
Kind
B2
Abstract

The principles and embodiments of the present invention relate to methods and systems for safely providing NO to a recipient for inhalation therapy. There are many potential safety issues that may arise from using a reactor cartridge that converts NO 2 to NO, including exhaustion of consumable reactants of the cartridge reactor. Accordingly, various embodiments of the present invention provide systems and methods of determining the remaining useful life of a NO2-to-NO reactor cartridge and/or a break-through of NO 2 , and providing an indication of the remaining useful life and/or break-through.

Claims (32)

1. A system for safely delivering a supply of nitric oxide (NO) to a recipient, comprising:

a gas source that supplies a gas, wherein the gas supplied by the gas source is nitrogen dioxide (NO 2 );

a gas conduit connected to and in fluid communication with the gas source;

a NO 2 -to-NO reactor cartridge connected to and in fluid communication with the gas conduit, so as to allow gas to flow from the gas source to an inlet end of the NO 2 -to-NO reactor cartridge, wherein the NO 2 -to-NO reactor cartridge comprises a consumable conversion media;

one or more sensor probe(s) configured to monitor functioning of the NO 2 -to-NO reactor cartridge operatively associated with the NO 2 -to-NO reactor cartridge, wherein the one or more sensor probe(s) are embedded into the consumable conversion media and the one or more sensor probe(s) is a moisture sensor configured to determine an amount of moisture present in the consumable conversion media;

a delivery conduit connected to and in fluid communication with an outlet end of the NO 2 -to-NO reactor cartridge, wherein the delivery conduit is operable to allow NO gas from the NO 2 -to-NO reactor cartridge to flow to the recipient;

a computer in electronic communication with the one or more sensor probe(s) over a communication path, wherein the computer is configured to receive electronic signals from the one or more sensor probe(s) and calculate a performance value; and

a regulating means in electronic communication with the computer over a communication path, wherein the regulating means is controlled based on the performance value.

2. The system of claim 1 , further comprises a flow meter for measuring an amount of gas entering the NO 2 -to-NO reactor cartridge.

3. The system of claim 1 , further comprises a flow meter for measuring an amount of gas being delivered to the recipient.

4. The system of claim 1 , further comprises an NO 2 sensor operationally associated with the delivery conduit configured to a presence of an unacceptable level of NO 2 in the gas being directed to the recipient.

5. The system of claim 1 , wherein the performance value is calculated and utilized for comparison with a predetermined threshold value, the computer is configured to generate an actuating signal when the performance value falls below the threshold value, and the regulating means is configured to receive the actuating signal from the computer, wherein the regulating means is configured to halt the delivery of the gas to a recipient when the actuating signal is received from the computer.

6. The system of claim 5 , wherein the threshold value indicates that a predetermined amount of the consumable conversion media has been reached, and wherein the computer is configured to alert a user through a display, an audible alarm, or both that the NO 2 -to-NO reactor cartridge is exhausted or compromised.

7. The system of claim 1 , wherein the one or more sensor probe(s) is configured to further detect or measure the concentration of ascorbic acid, the concentration of dehydroascorbic acid, the concentration of water (H 2 O), the concentration of NO 2 , the concentration of NO, the concentration of O 2 , the concentration of HNO 3 , the pH of at least a portion of the NO 2 -to-NO reactor cartridge, the redox potentials of chemical species in the NO 2 -to-NO reactor cartridge, the mass flow rate of gases, the conductance at the surface of the silica gel, or combinations thereof.

8. A method of monitoring the performance of a nitrogen dioxide (NO 2 )-to-nitric oxide (NO) reactor cartridge, the method comprising:

incorporating one or more sensor probe(s) into an NO 2 -to-NO reactor cartridge comprising a conversion media, wherein the one or more sensor probe(s) are operatively associated with the NO 2 -to-NO reactor cartridge and the one or more sensor probe(s) is a moisture sensor configured to determine the amount of moisture present in the conversion media; and

operatively associating at least one meter with the one or more sensor probe(s) and wherein the one or more sensor probe(s) are embedded into the conversion media; calculating a performance value based on electronic signals from the one or more sensor probe(s); and controlling a regulating means based on the performance value.

9. The method of claim 8 , which further comprises incorporating the NO 2 -to-NO reactor cartridge into an NO delivery system, wherein the NO 2 -to-NO reactor cartridge is connected to and in fluid communication with a gas source conduit that is configured to contain and direct a gas from a gas source to the NO 2 -to-NO reactor cartridge.

10. The method of claim 9 , which further comprises detecting physical and/or chemical characteristics of the conversion media with the one or more sensor probe(s);

measuring the detected physical and/or chemical characteristics with the operatively associated meter;

communicating the measured physical and/or chemical characteristics to a computer; and monitoring the communicated characteristics with the computer.

11. The method of claim 8 , wherein the conversion media comprises a packing material coated with ascorbic acid, alpha tocopherol, or gamma tocopherol, and a color agent.

12. A system for safely delivering a supply of nitric oxide (NO) to a recipient, comprising:

a gas source that supplies a gas, wherein the gas is nitrogen dioxide (NO 2 ) or NO;

a gas conduit connected to and in fluid communication with the gas source;

a NO 2 -to-NO reactor cartridge connected to and in fluid communication with the gas conduit, so as to allow gas to flow from the gas source to an inlet end of the NO 2 -to-NO reactor cartridge, wherein the NO 2 -to-NO reactor cartridge comprises a consumable conversion media;

one or more sensor probe(s) configured to monitor functioning of the NO 2 -to-NO reactor cartridge operatively associated with the NO 2 -to-NO reactor cartridge, wherein the one or more sensor probes are embedded into the consumable conversion media and the one or more sensor probe(s) is a moisture sensor configured to determine an amount of moisture present in the consumable conversion media;

a delivery conduit connected to and in fluid communication with an outlet end of the NO 2 -to-NO reactor cartridge, wherein the delivery conduit is operable to allow NO gas from the NO 2 -to-NO reactor cartridge to flow to the recipient;

a computer in electronic communication with the one or more sensor probe(s) over a communication path, wherein the computer is configured to receive electronic signals from the one or more sensor probe(s) and calculate a performance value for comparison with a predetermined threshold value, and configured to generate an actuating signal when the performance value falls below the threshold value; and

a regulating means in electronic communication with the computer over a communication path, wherein the regulating means is configured to receive the actuating signal from the computer, and wherein the regulating means halts the delivery of the gas to a recipient.

13. The system of claim 12 , wherein the NO 2 -to-NO reactor cartridge comprises an outer reactor shell, an inlet, an outlet, and the consumable conversion media including solid packing material coated with consumable reactant.

14. The system of claim 12 , wherein the gas source is encased within an outer housing.

Assignments (11)
SECURITY INTEREST Recorded Oct 28, 2025
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: GOLDMAN SACHS BANK USA, AS ADMINISTRATIVE AGENT
Reel/Frame 073375/0395 →
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
SECURITY INTEREST Recorded Aug 1, 2025
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 072331/0001 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 043601, FRAME 0025 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065610/0233 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →